Therapeutic antibody engineering for efficient targeted degradation of membrane proteins in lysosomes.

AMFA Antibody engineering Lysosome Mannose 6-phosphate receptor Mannose 6-phosphonate Targeted protein degradation

Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
12 May 2024
Historique:
received: 10 02 2024
revised: 30 04 2024
accepted: 02 05 2024
medline: 14 5 2024
pubmed: 14 5 2024
entrez: 13 5 2024
Statut: aheadofprint

Résumé

Targeted degradation of pathological proteins is a promising approach to enhance the effectiveness of therapeutic monoclonal antibodies (mAbs) in cancer therapy. In this study, we demonstrate that this objective can be efficiently achieved by the grafting of mannose 6-phosphate analogues called AMFAs

Identifiants

pubmed: 38739989
pii: S0753-3322(24)00591-2
doi: 10.1016/j.biopha.2024.116707
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116707

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper

Auteurs

Corentin Gauthier (C)

NanoMedSyn, Montpellier, France; Institut des Biomolécules Max Mousseron (IBMM), University of Montpellier, CNRS, ENSCM, Montpellier, France.

Morgane Daurat (M)

NanoMedSyn, Montpellier, France.

Lamiaa Mohamed Ahmed Ali (LMA)

Institut des Biomolécules Max Mousseron (IBMM), University of Montpellier, CNRS, ENSCM, Montpellier, France; Department of Biochemistry, Medical Research Institute, University of Alexandria, Alexandria 21561, Egypt.

Khaled El Cheikh (K)

NanoMedSyn, Montpellier, France.

Iris El Bahlagui (I)

NanoMedSyn, Montpellier, France.

Camille Taliercio (C)

NanoMedSyn, Montpellier, France.

Elodie Morère (E)

NanoMedSyn, Montpellier, France; Institut des Biomolécules Max Mousseron (IBMM), University of Montpellier, CNRS, ENSCM, Montpellier, France.

Magali Gary-Bobo (M)

Institut des Biomolécules Max Mousseron (IBMM), University of Montpellier, CNRS, ENSCM, Montpellier, France.

Alain Morère (A)

Institut des Biomolécules Max Mousseron (IBMM), University of Montpellier, CNRS, ENSCM, Montpellier, France.

Marcel Garcia (M)

NanoMedSyn, Montpellier, France.

Marie Maynadier (M)

NanoMedSyn, Montpellier, France.

Ilaria Basile (I)

NanoMedSyn, Montpellier, France. Electronic address: i.basile@nanomedsyn.com.

Classifications MeSH